Src-bcr-Abl Src-bcr-Abl

Cat.No.	Name	Information
M2331	PP2	PP2 (AGL 1879) is a selective inhibitor of Src-family tyrosine kinases with >10,000-fold selectivity over ZAP-70 and JAK2.
M1701	Dasatinib	Dasatinib (BMS-354825) is a small molecule inhibitor of both the SRC and BCR/ABL tyrosine kinases, with IC50's for the isolated kinases of 0.55 and 3.0 nM, respectively.
M1648	AP24534	Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor of BCR-ABL, PDGFRα, c-Src, c-Kit, FGFR and VEGFR.
M1799	Imatinib Mesylate	Imatinib Mesylate is a Bcr-Abl tyrosine kinase inhibitor, with IC50 values of 2.9 and 3.9 μM for the inhibition of T-cell proliferation stimulated by PHA and DCs respectively.
M1685	Bosutinib	Bosutinib (SKI-606) is a novel Bcr-Abl inhibitor with IC50 values of 0.1 to 0.3 umol/L.
M3194	Nocodazole	Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM, respectively.
M2953	PP1	PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
M2917	PD173955	PD173955 is a potent Bcr-Abl inhibitor with IC50 of 1-2 nM, also inhibiting Src activity with IC50 of 22 nM.
M2862	MNS	MNS is a tyrosine kinases inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.
M2749	Olverembatinib dimesylate	Olverembatinib (GZD824) dimesylate is a third-generation oral effective BCR-ABL inhibitor, acting on BCR-ABL (WT) and BCR-ABL (T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
M2603	GNF-5	GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).
M2571	GNF-2	GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.
M2313	Tirbanibulin (KX2-391)	Tirbanibulin (KX2-391) is a First-in-Class, highly selective non ATP-competitive Src inhibitor with GI50 of 9-60 nM in cancer cell lines .
M1991	Bafetinib	Bafetinib (NS-187, INNO-406) is a novel second-generation dual Bcr-Abl/Lyn tyrosine kinase inhibitor.
M1912	Nilotinib	Nilotinib (AMN107) is a small molecule Bcr-Abl kinase inhibitor with IC50 less than 30 nM.
M1702	DCC-2036	DCC-2036 is an ABL inhibitor with IC50 of 0.8 and 2 nM for u-ABL1native and p-ABL1native, respectively.
M1659	Saracatinib	Saracatinib (AZD0530) is an orally active small molecule Src inhibitor.
M57215	KB SRC 4	KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.
M57186	Hydroxymethyl dasatinib	Hydroxymethyl dasatinib (M24), a benzylhydroxy metabolite of Dasatinib, exhibits an IC50 of 46.7nM in K562 CML cells.
M54849	Asciminib hydrochloride	Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.
M50427	Abl Cytosolic Substrate	Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).
M50411	Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH	Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM).
M50410	p60c-src substrate II	p60c-src substrate II is an efficient pentapeptide substrate for the tyrosine kinase pp60c-src.
M50409	Caffeic acid-pYEEIE	Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.
M50408	Secretin, canine	Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids.
M50407	RR-SRC	RR-SRC is a substrate for src-tyrosine-specific protein kinase.

By Signaling Pathways

By Product Type

Signaling Pathways

Src-bcr-Abl Src-bcr-Abl

Get to Know Us

Customer Support

Resources

Contact Us